Renascience

Renascience Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Renascience (4889.T) as of Nov 19, 2026 is 96.69 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was -155.47 % — a change of -162.19% (higher).

Cash Conversion

96.69 %

YoY

-162.19%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Renascience is 2026 96.69 % . Cash Conversion Rate (OCF/Net Income) of Renascience was 2025 -155.47 % . It decreases by -162.19% higher compared to the previous year.

The Renascience Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2020
96.91 JPY
Jan 1, 2021
89.21 JPY
Jan 1, 2022
90.64 JPY
Jan 1, 2023
84.77 JPY
Jan 1, 2024
89.23 JPY
Jan 1, 2025
-155.47 JPY
Jan 1, 2026
96.69 JPY
The Renascience Cash Conversion history
YEARCash ConversionYoY
96.69 %-162.19%
-155.47 %-274.23%
89.23 %+5.27%
84.77 %-6.48%
90.64 %+1.61%
89.21 %-7.95%
96.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Cash Conversion Rate (OCF/Net Income) of Renascience is 96.69 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Renascience changed from -155.47 % to 96.69 %, representing a -162.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Renascience since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Renascience

All Key Metrics — Renascience